PledPharma receive research grant to the ongoing phase II clinical trial

PledPharma, Linköping University and Ryhov County Hospital receive research grant to the ongoing phase II clinical trial in patients with acute myocardial infarction

PledPharma AB has together with Linköping University and Ryhov County Hospital in Jönköping received 250 000 Swedish kronor from the Research Council of the South East Sweden (FORSS) to the ongoing clinical study

The trial is run at the County Hospital Ryhov in Jönköping, Sweden, and Dr Jan-Erik

Karlsson at the Department of Internal Medicine serves as the project leader and principal investigator.

Active reopening of occluded coronary arteries by primary percutaneous coronary

intervention (PCI) has led to reduction in infarct size, but there is still a need for

improvement.

The aim of the present project is to test whether PP-099, a LowMEM (Low Molecular weight Enzyme Mimetic), further reduces myocardial infarct size in patients undergoing primary PCI. Preclinical studies indicate that PP-099 may reduce myocardial infarct size by more than 50%.

For further information, please contact:

Per Jynge, Medical Director, PledPharma AB, +47 735 115 55

Jan Olof G. Karlsson, Chief Scientific Officer, PledPharma AB, +46 733 304 624

PledPharma AB develops new medicines based on Low Molecular weight Enzyme Mimetics

(LowMEM) with an initial candidate PP-095 for oncology. PP-095 protects against dose-limiting side effects during cancer therapy with cytostatic drugs, without diminishing the anticancer effect. PP-095 entered clinical phase II trials in cancer patients in 2008. In addition to cancer treatment, LowMEMs have a wide range of potential indications, e.g., myocardial infarction, stroke and neurodegenerative diseases. For more information see www.pledpharma.se